Belgium· BE-AMP-SAM016256-00

Cerulyx 4.55 %

A indifferent preparations product containing xylol, registered in Belgium by Bausch + Lomb Ireland. The same ATC class is registered in 2 of our 19 countries.

ATC S02DC

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedCerulyx 4.55 %ATCS02DCREGISTER NO.BE-AMP-SAM016256-00PACKS LISTED1CHECKEDSeptember 26, 2026

Where it is registered

Xylol is registered in 2 of 19 countries.

Countries holding a registration under ATC S02DC (indifferent preparations), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 1 of them publish a price we can compare per daily dose

Xylol · ATC S02DC

2 / 19 countries

  • Belgiumprice
  • Ireland
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Xylol
Manufacturer
Bausch + Lomb Ireland
Country
Belgium (BE)
ATC code
S02DC
ATC class
Indifferent preparations
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 1

  • be_apb
    0105965

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Xylol in 1 other country

What each register calls a product with the same active substance — salts and hydrates count as the same.

All xylol products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • France · Cerulyse
  • Luxembourg · Cerulyx

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9bd7305b-f307-4881-a427-0ec1effb1f1e
GET /v1/drugs/9bd7305b-f307-4881-a427-0ec1effb1f1e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Ear drops, solution",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Cerulyx 4.55 %",
  "name_fr": "Cerulyx 4.55 %",
  "name_nl": "Cerulyx 4.55 %",
  "amp_code": "SAM016256-00",
  "strengths": [
    "50.0000",
    "455.0000",
    "455.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Xylol",
    "Xylene"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Indifferent Preparations",
  "authorisation_numbers": [
    "BE016256"
  ]
}

See everything about xylol.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.